HCS Pharma (HCS) STO 評価と詳細

2022/04/08

2022/06/08

100% 完成した

$209 720 767

28% ゴール完成した

734 022 685.00 USD

past

1 HCS

=

500 USD

トークンの詳細

ティッカー

HCS

総供給

€ 7 million

トークン配布

European Digital Asset Exchange | https://www.edsx.ch/projects/hcs-pharma

許容通貨

BTC, CHF, EUR, USDT, DOLLAR

最小の貢献

500

TOKEN

会社の詳細

登録会社名

HCS Pharma SAS

登録国

France

設立された会社

Jan 1, 2014

ボーナス構成

20% discount offered on final share price

追加の詳細

プラットフォーム

eos

カテゴリー

プラットフォーム

約 HCS Pharma

HCS Pharma is a biotechnology company focused on in vitro R&D, specializing in high content (HCA) and high throughput (HCS) cell imaging screening. HCS Pharma sells products based on BIOMIMESYS® technology, and develops its own 3D cellular models in its proprietary BIOMIMESYS® extracellular matrix. BIOMIMESYS® 3D culture technology faithfully reproduces the natural microenvironment of cells in 3D, to ensure more predictive results from in vitro studies, to reduce the time and cost of R&D, and animal testing in pharmaceutical, nutraceutical and cosmetic companies. BIOMIMESYS® technology is also requested to be used in cell therapy and regenerative medicine, allowing HCS Pharma to become the leader in all biotechnology industries in the next 5 years.

特徴

BIOMIMESYS® is a unique groundbreaking 3D cell culture technology which associates the behavior of a solid scaffold and of a hydrogel which provide a cell culture microenvironment reproducing all aspects of human tissues, including matrix architecture, cellular organization, cell-cell and cell-matrix interactions.

Depending on the organ, extracellular matrix components may vary as well their proportions, allowing a more or less dense and compact cellular environment (different Elastic Modulus, porosity).

BIOMIMESYS® matrices are made of Hyaluronic Acid (HA), the main glycosaminoglycan (GAG) of the ECM, collagens and adhesion proteins. Our patented manufacturing process allow preserving the natural properties of HA and therefore synthesizing proprietary Hydroscaffold™.

技術情報

HCS Pharma owns 2 cell culture labs and one automation lab equipped with a robotic platform named HAPIx, including 2 confocal HCS systems, ImageXpress micro confocal systems from Molecular Devices, and a ImageXpress micro XLS also from Molecular Devices and a chemical lab for BIOMIMESYS® production.

％name％ロードマップ

18 months

- 6 months: Development of a sales force in the different countries in Europe.

- 1 year: New production line set up + Development of a technical support center in Taiwan + fundraising and/or IPO project.

- 18 months: Presence in the US.

10 Years

- In 3 years, from patient cells, we will be able to recreate small diseased organs to test molecules and find the most suitable therapy for personalized medicine.

- In 5 years, we will be able to find much more effective clinical drug candidates and therefore ultimately treat patients with cancer, Parkinson's disease, or Alzheimer's.

- In 10 years, we will be able to recreate complete organs for organ transplantation. And from animal cells, we will be able to recreate muscle and therefore cultured meat.

HCS Pharma チーム

検証済み 25%

注意。確認されていないメンバーは実際にチームのメンバーではないというリスクがあります

Nathalie Maubon

CEO

検証済み

Elodie Vandenhaute

Project Manager

Zied Souguir

Biomaterial Department Manager

Gregory Maubon

Chief Development Officer and IA Project Leader

顧問

検証済み 100%

Mauro Andriotto

Advisor

検証済み

HCS Pharma インタビュー

Mauro Andriotto

As a team member, сan you tell us about your role in the ICO project?

I am the CEO of the European Digital Assets Exchange where HCS Pharma is listed on the primary market.

What do you think about idea?

It's an amazing company selected by the European Commission between the most 50 most disruptive biotech in Europe and there is the plan to list the company on the Frankfurt Stock Exchange by the end of the year.

Nathalie Maubon

As a team member, сan you tell us about your role in the ICO project?

We have decided to go public before the end of the year by a Reverse Take Over (RTO) with a pre-IPO fund-raising such as STO. This STO in pre-IPO will give the possibility to crypto investors to be onboarded.

What do you think about idea?

This STO coupled with the STO makes it possible to rally virtual currency investors with the traditional market.